The robots aren't coming. They're already here. From assembly lines and warehouse operations to surgical centers and home assistants, the robot revolution is in full-swing. But while regular people today are using robots to vacuum their homes and turn off their lights, a growing number of companies are pushing into the red hot field of robotics on a much larger scale. That makes now a great time to look at robotics stocks to buy. There appears to be no slowing down the momentum behind robots, especially wit ...

TROY, Mich., June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) as its "Stock to Study" and Medtronic PLC (NYSE: MDT) as its "Undervalued Stock" in the September 2024 issue for investors' informational and educational use. "With GameStop back in the headlines, the siren song of easy money has returned, luring the unschooled down treacherous paths. The National Association of Investors ...

A team of surgeons operate on a patient in the operating room. JohnnyGreig Centering my portfolio around high-quality dividend stocks, I tend to be very much in tune with the get rich slowly mindset. This is because, in my view, the speculation that leads to overnight wealth is unsustainable. The same wealth that was built overnight can be lost just as quickly. That's why I take a long-term, fundamentals-driven investing approach. Before I get into the dividend stock that I'm highlighting today, I just want ...

They aren't the flashiest stocks, but they get the job done. Few industries are more essential than healthcare. That makes it an excellent place to look for stocks that can perform well over extended periods since the basic services they offer are unlikely to become obsolete anytime soon. However, that doesn't guarantee success for any individual corporation. Even the healthcare sector changes and evolves in important ways. Only innovative companies can remain relevant over the long run. And some of them ca ...

JHVEPhoto MDT stock: Buy rating meets insider selling The prevailing sentiment surrounding Medtronic plc (NYSE:MDT) stock is very bullish as you can see from the chart below. The chart shows that both Seeking Alpha writers and Wall Street analysts rate MDT as a buy. To wit, Wall Street analysts have a majority buy rating on MDT, with 11 analysts recommending a strong buy and 5 recommending a buy (out of 33 analysts in the last 90 days). Only 2 analysts recommend selling the stock. Seeking Alpha writers have ...

会议主要讨论的核心内容 - 公司在过去几年中的战略重点包括加速创新、提升运营能力、培养以绩效为导向的企业文化 [4][5][6][7][8] - 公司的创新战略是成功之道,因为医疗技术行业正在经历真正的增长,受益于人口老龄化和新技术的推动 [10][11][12][13][14][16] - 公司的核心业务如心脏节律管理和脊柱外科保持健康增长,得益于新技术的应用,如无导线起搏器和导电系统起搏器 [23][24][25][26][27] - 公司的机器人手术业务Hugo即将在美国获批,商业化策略是将其打包纳入公司的整体外科手术产品组合 [28][34][35][39][40] - 公司的心律失常消融业务增长迅猛,新一代PFA技术正在快速取代射频和冷冻消融技术 [45][46][47][48][49] - 公司的肾脏去神经刀术业务正在等待美国医疗保险体系的全面报销政策,这将是推动该业务全球加速的关键 [61][62][63][64] - 公司的TAVR业务在欧洲面临一定的价格竞争,但公司的新一代产品在临床数据上明显优于竞争对手 [65][66][67][68][69][70][71][72] 问答环节重要的提问和回答 问题1 **David Roman 提问** 公司如何看待GLP-1药物对其业务的影响 [17] **Geoff Martha 回答** GLP-1药物对公司的手术业务有一定影响,但影响有限,公司的糖尿病业务仍在快速增长 [18][19] 问题2 **David Roman 提问** 公司如何看待未来一年的收入增长前景 [20] **Geoff Martha 回答** 公司给出的4%-5%的收入增长指引是保守的,考虑到公司在高增长领域的新产品发布,以及过去几个季度的中单位数增长 [21] 问题3 **David Roman 提问** 公司如何看待未来几年的利润增长前景 [80][81][82][83][84][85][86][87][88][89][90][91][92][93][94] **Geoff Martha 回答** 公司有信心通过提升运营效率、产品组合优化等措施,实现中高单位数的利润增长,并逐步提升毛利率水平

文章核心观点 - 美敦力是一家全球领先的医疗技术公司,总部位于爱尔兰都柏林 [1] - 美敦力将参加2024年6月11日在纽约举行的第45届高盛全球医疗保健会议 [1][2] - 美敦力董事长兼首席执行官Geoff Martha将在会议上回答有关公司的问题 [2] - 会议的问答环节将通过网络直播的方式提供 [3] 公司概况 - 美敦力是一家全球领先的医疗技术公司,总部位于爱尔兰都柏林 [1] - 公司拥有95,000多名员工,业务遍及150个国家 [4] - 公司的产品和疗法涵盖70种健康状况,包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等 [4] - 公司的使命是缓解痛苦、恢复健康和延长生命 [4] - 公司致力于提供创新技术,每秒、每小时、每天改善两个人的生活 [4] 财务信息 - 无 行业信息 - 无

Medtronic is keeping its dividend streak going, but the recent increase isn't likely to be a meaningful one for many dividend investors. Dividend growth stocks can make for excellent long-term investments. Their ongoing rate increases allow investors to generate more in dividend income than if they were to just invest in a stale dividend with no increases, and which inflation chips away at over time. Medical device maker Medtronic (MDT -1.15%) falls into the category of a dividend growth stock. The company, ...

文章核心观点 - 公司宣布其全资间接子公司Medtronic, Inc.已发行了总计28亿欧元的4只高级债券 [1][2] - 债券发行所得将用于公司一般性用途,包括偿还未偿商业票据和其他债务 [2] - 公司是全球领先的医疗技术公司,致力于解决人类最具挑战性的健康问题 [4] 公司概况 - 总部位于爱尔兰都柏林,是全球领先的医疗技术公司 [4] - 拥有95,000多名员工,业务遍及150个国家 [4] - 公司的技术和疗法涵盖70种健康状况,包括心脏设备、手术机器人、胰岛素泵等 [4] - 公司致力于提供创新技术,改善人们的生活质量 [4] 债券发行情况 - 公司全资间接子公司Medtronic, Inc.发行了4只高级债券 [1] - 债券总额为28亿欧元,期限分别为2029年、2036年、2043年和2053年 [1] - 债券由公司和其全资子公司Medtronic Global Holdings S.C.A.提供全额无条件担保 [1] - 本次债券发行预计于2024年6月3日完成,由花旗、摩根大通、美银和瑞穗担任联席簿记管理人 [2][3]

文章核心观点 - 医疗设备制造商Medtronic连续47年提高了股息支付 [1][6][7] - 尽管Medtronic最新季度业绩公布后股价下跌5%,但一些分析师仍看好公司前景 [2][3][4] - Medtronic在创新医疗设备市场拥有强大优势,其MiniMed 780G系统获得FDA批准 [8][9] - Medtronic持续加大研发投入,近期获批多款新产品,预计未来几年收入和利润将保持中单位数增长 [10][11][12] 根据相关目录分别进行总结 公司概况 - Medtronic是一家医疗设备制造商,拥有47年连续增加股息的历史 [1][6][7] - 公司在创新医疗设备领域具有强大优势,擅长获得监管部门的产品批准 [8][9] 财务表现 - 公司最新一季度业绩公布后股价下跌5%,但分析师仍看好公司前景 [2][3][4] - 公司持续加大研发投入,近期获批多款新产品,预计未来几年收入和利润将保持中单位数增长 [10][11] 新产品动态 - Medtronic获批MiniMed 780G系统,可自动监测血糖并给予胰岛素 [8] - 公司还获批新的经导管主动脉瓣置换系统、脊髓刺激器等产品 [10] - 公司还与英伟达合作开发内窥镜AI辅助聚糜产品GI Genius [12]